--- title: "Rigel Pharmaceuticals (RIGL) stock and investor profile" url: "https://aibio.space/companies/rigel-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL), United States. The directory classifies it as Pharmaceuticals: Major." --- RIGL Rigel Pharmaceuticals, Inc. NASDAQ · United States # Rigel Pharmaceuticals (RIGL) news Mergers · 2026-06-17 ## [Rigel Pharmaceuticals completes vepdegestrant license, pays $70.0 million upfront](https://aibio.space/news/rigel-pharmaceuticals-completes-vepdegestrant-license-pays-70-0/) The license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million. ## Latest Rigel Pharmaceuticals news 1. 2026-06-17 Mergers [Rigel completes vepdegestrant license from Arvinas and Pfizer, pays $70.0 million](https://aibio.space/news/rigel-completes-vepdegestrant-license-arvinas-pfizer-pays-70-0-million/) Rigel paid the licensors a one-time upfront payment of $70.0 million after the antitrust waiting period ended early. The 8-K describes no milestones, royalties or clinical details for the drug. 2. 2026-04-21 Distress [Lilly to end Rigel ocadusertib license effective June 15, 2026](https://aibio.space/news/lilly-end-rigel-ocadusertib-license-effective-june-15-2026/) Eli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement. ## Rigel Pharmaceuticals at a glance - **Ticker**: RIGL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $95.3 million ### Related companies - [Vaxxinity](https://aibio.space/companies/vaxxinity/) OTC: VAXX - [Acumen Pharmaceuticals](https://aibio.space/companies/acumen-pharmaceuticals/) NASDAQ: ABOS - [Cytokinetics](https://aibio.space/companies/cytokinetics/) NASDAQ: CYTK - [Corcept Therapeutics](https://aibio.space/companies/corcept-therapeutics/) NASDAQ: CORT - [ARS Pharmaceuticals](https://aibio.space/companies/ars-pharmaceuticals/) NASDAQ: SPRY - [Acura Pharmaceuticals](https://aibio.space/companies/acura-pharmaceuticals/) OTC: ACUR - [Supernus Pharmaceuticals](https://aibio.space/companies/supernus-pharmaceuticals/) NASDAQ: SUPN - [Nektar Therapeutics](https://aibio.space/companies/nektar-therapeutics/) NASDAQ: NKTR ### Also on NASDAQ - [Rocket Pharmaceuticals](https://aibio.space/companies/rocket-pharmaceuticals/) RCKT - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) AGIO - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) CGTX - [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) SNTI - [Compugen](https://aibio.space/companies/compugen/) CGEN - [GT Biopharma](https://aibio.space/companies/gt-biopharma/) GTBP ## Rigel Pharmaceuticals annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$294.3 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | [$179.3 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | | Research and development | [$33.3 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | [$23.4 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | | Net income (loss) | [$367.0 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | [$17.5 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | | Cash from operations | [$75.7 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | [$31.5 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | | Cash and equivalents | [$40.6 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000052/) | [$56.7 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | | Short-term investments | [$114.4 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000052/) | [$20.6 million](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000015/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $60.8 million, plus short-term investments of $34.5 million, $95.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Rigel Pharmaceuticals What is the ticker symbol of Rigel Pharmaceuticals? Rigel Pharmaceuticals, Inc. trades under the ticker RIGL on NASDAQ. Where is Rigel Pharmaceuticals listed? Rigel Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:RI2; LS:A40EFY. What is the SEC CIK of Rigel Pharmaceuticals? The SEC Central Index Key (CIK) for Rigel Pharmaceuticals, Inc. is 1034842. Its filings are on SEC EDGAR. How many shares does Rigel Pharmaceuticals have outstanding? 18,679,864 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-04. Which country or territory is Rigel Pharmaceuticals listed under? Our directory records Rigel Pharmaceuticals, Inc. under United States. What does Rigel Pharmaceuticals do? Our directory classifies Rigel Pharmaceuticals, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Rigel Pharmaceuticals? The ISIN recorded for Rigel Pharmaceuticals, Inc. is US7665597024. Does aibio.space cover Rigel Pharmaceuticals? aibio.space lists Rigel Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Rigel Pharmaceuticals incorporated? SEC records list its state or country of incorporation as DE. What was Rigel Pharmaceuticals's revenue last year? $294.3 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Rigel Pharmaceuticals profitable? Rigel Pharmaceuticals, Inc. reported net income of $367.0 million for the fiscal year ended Dec 31, 2025, and generated $75.7 million of cash from operations, per its annual report to the SEC. How much does Rigel Pharmaceuticals spend on research and development? $33.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Rigel Pharmaceuticals have? $95.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Rigel Pharmaceuticals (RIGL) stock news? Our latest story on Rigel Pharmaceuticals, dated Jun 17, 2026: "Rigel Pharmaceuticals completes vepdegestrant license, pays $70.0 million upfront". The license for VEPPANU (vepdegestrant) became effective after the Hart-Scott-Rodino waiting period ended early. Rigel paid the licensors, Arvinas and Pfizer, a one-time upfront payment of $70.0 million. [Source](https://aibio.space/news/rigel-pharmaceuticals-completes-vepdegestrant-license-pays-70-0/). Is Rigel Pharmaceuticals in financial distress? Our latest distress story, dated Apr 21, 2026: "Lilly to end Rigel ocadusertib license effective June 15, 2026". Eli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement. [Source](https://aibio.space/news/lilly-end-rigel-ocadusertib-license-effective-june-15-2026/). ## Investor discussion: Rigel Pharmaceuticals Members talk about Rigel Pharmaceuticals (RIGL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Rigel Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-06-17 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01). [Source](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/rigl-20260611.htm) 2. 2026-04-21 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000027/rigl-20260416.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RIGL on TradingView](https://www.tradingview.com/symbols/NASDAQ-RIGL/). ## SEC filings and registration - **SEC name**: Rigel Pharmaceuticals Inc - **CIK**: 1034842 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: RIGL (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Accelerated filer - **Business address**: 611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-624-1100 - **Shares outstanding**: 18,679,864 as of 2026-07-30 (10-Q filed 2026-08-04) - **Former names**: RIGEL PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000053/rigl-20260804.htm) filed 2026-08-04 - [10-Q](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000052/rigl-20260630.htm) filed 2026-08-04 - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000045/rigl-20260625.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000043/rigl-20260611.htm) filed 2026-06-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000041/rigl-20260514.htm) filed 2026-05-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/rigl-20260511.htm) filed 2026-05-12 - [8-K](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000033/rigl-20260505.htm) filed 2026-05-05 - [10-Q](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000032/rigl-20260331.htm) filed 2026-05-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001034842), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Rigel Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RIGL, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Rigel Pharmaceuticals, Inc. - **Ticker**: RIGL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US7665597024 - **Other listed symbols**: GETTEX:RI2; LS:A40EFY - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RIGL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/rigel-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rigel Pharmaceuticals (RIGL) stock and investor profile", 2026-10-31, https://aibio.space/companies/rigel-pharmaceuticals/